Issue link: https://www.e-digitaleditions.com/i/1208415
6 FEBRUARY 2020 Inhalation For more information on IPAC-RS, or to join, please visit www.ipacrs.org. nia. e symposium is titled " e Global Regulatory Landscape and Advances in Digital Technology: Transforming the Patient Expe- rience with OINDPs." A series of podium presentations and a panel discussion will be held on the morning of ursday, April 30, as part of the RDD 2020con- ference program. e IPAC-RS Symposium will continue on the afternoon of ursday, April 30 through Friday, May 1. In 2020, IPAC-RS will continue developing a "Matrix of Common Use Errors," nalizing a manu- script on "Aerodynamic Particle Size Assessment of Orally Inhaled Products," conducting a biocom- patibility survey, developing a manuscript on plume geometry and spray pattern, and discuss- ing statistical approaches around product quality demonstration strategy for quality assessments and PK batch-to-batch variability in bioequivalence assessments. In the broader stakeholder community Following the November 2018 Materials Summit, where IPAC-RS actively engaged with materials, device and packaging component suppliers and regulators, the Con- sortium held joint workshops with Drug Delivery to the Lungs (DDL) in Scotland (December 2018) and the International Society for Aero- sols in Medicine (ISAM) on Digi- tal Health in Respiratory Products in Switzerland (May 2019). Seven publications on topics rang- ing from plume geometry to inter- national OINDP requirements and harmonization, PBE, aero- dynamic particle size distribu- tion and cascade impactor equiv- alence testing served to highlight IPAC-RS' key learnings. Future focus IPAC-RS is anticipating a pro- ductive 2020 and is planning for the joint IPAC-RS/RDD sym- posium in Palm Desert, Califor- About IPAC-RS e International Pharma- ceutical Aerosol Consor- tium on Regulation & Sci- ence (IPAC-RS) is an inter- national association that seeks to advance the science, and especially the regula- tory science, of orally inhaled and nasal drug products (OINDPs) by collecting and analyzing data, and conduct- ing joint research. IPAC-RS aims to build consensus and contribute to e ective regula- tions and standards by shar- ing the results of research through conferences, techni- cal journals and discussions with regulatory bodies. MARK YOUR CALENDAR AND PLAN TO ATTEND! R D D O N L I N E . C O M